Drugs / Ismigen
Ismigen
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 34 trials · 2 missed | ||||||
| Phase 3 | NCT04802616 | Mar → Sep 2021 | seasonal allergic rhinitis | Medical University of Lublin | Completed | No outcome recorded |
| Phase 3 | NCT04270552 | Apr → Jul 2018 | seasonal allergic rhinitis | Medical University of Lublin | Completed | No outcome recorded |
| Phase 3 | NCT04637425 | Apr 2018 → Aug 2020 | allergic rhinitis | Medical University of Lublin | Completed | Missed primary |
| Phase 3 | NCT02541331 | Jul 2014 → Jun 2015 | allergic asthma | Lallemand Pharma AG | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02417649 | Sep 2009 → Jul 2013 | chronic obstructive pulmonary disease | Lallemand Pharma AG | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07578012 Comparator | Jun 2026 → Mar 2027 expected | respiratory tract infectious disorder | Lallemand Pharma AG | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-05-05 | Lallemand Pharma AG | Results Scientific Paper: Mechanical bacterial lysate enhances antimicrobial barrier mechanisms in human airway epithelial cells lallemandpharma.com ↗
The results indicate that polyvalent mechanical bacterial lysate administration might support mucosal barrier integrity and promote mechanisms of antimicrobial activity in airway epithelial cells. |
| 2014-11-19 | Lallemand Pharma AG | Regulatory Lallemand Pharma and Merck continue ISMIGEN® marketing in Latin America lallemandpharma.com ↗
Lallemand Pharma and Merck are pleased to announce the launch in Dominican Republic of ISMIGEN®, an immuno-modulating drug developed and produced by Lallemand Pharma. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-05-05 | Lallemand Pharma AG | Scientific Paper: Mechanical bacterial lysate enhances antimicrobial barrier mechanisms in human airway epithelial cells lallemandpharma.com ↗ |
| 2021-05-03 | Lallemand Pharma AG | Ismigen: Award for the best clinical study in allergology published in 2020 lallemand.com ↗ |
| 2014-11-19 | Lallemand Pharma AG | Lallemand Pharma and Merck continue ISMIGEN® marketing in Latin America lallemandpharma.com ↗ |
| 2014-11-13 | Lallemand Pharma AG | Lallemand Pharma and Stada Cis Join forces to launch Ismigen in Russia lallemandpharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISMIGEN | “Ismigen® (Polyvalent Mechanical Bacterial Lysate; PMBL) which is manufactured by mechanical lysis is currently authorized in two EU Member States (MS), Italy and Poland, where...” NCT07578012 ↗ |
| Known as | mechanic Polyvalent Bacterial Lysate | “The use of a mechanic Polyvalent Bacterial Lysate (PMBL, Ismigen, 13 bacterial strains)may enhance the immune response and therefore help significantly to the control of...” NCT02417649 ↗ |
| Known as | PMBL | “The use of a mechanic Polyvalent Bacterial Lysate (PMBL, Ismigen, 13 bacterial strains)may enhance the immune response and therefore help significantly to the control of...” NCT02417649 ↗ |
| Modality | Vaccine | “full-fledged antibacterial oral vaccination” NCT02541331 ↗ |
| Route | Other | “Sublingual use” NCT02541331 ↗ |